An updated BCR-ABL1 t[9;22] RT-PCR assay went live on Jan 31, 2018. The BCR-ABL major and minor fusion transcripts are measured and reported separately after this update. The quantities of BCR-ABL1 major breakpoints fusion transcripts (type e13a2 and/or e14a2) are detected by FDA approved QuantideX® qPCR BCR-ABL IS Kit and the result is calibrated and reported on the International Scale (%IS). The quantities of BCR-ABL minor fusion transcripts are detected by QuantideX qPCR BCR-ABL minor kit and the result is reported as BCR-ABL1 to ABL1 ratio (%). This update provides more precise and standard measurements of BCR-ABL fusion RNA and supports the consistency of patient care in t(9;22) positive CML patients during monitoring of treatment with Tyrosine Kinase Inhibitors (TKIs).
Questions may be directed to the Molecular Diagnostics Laboratory using the “Contact Us” link above.
Lab Catalog link: LAB3222022: BCR-ABL1 t[9;22] RT- PCR
Spectrum Health Advanced Technology Laboratories are proud to announce that the first and only FDA-approved blood test for colorectal cancer screening is now available at Spectrum Health Molecular Diagnostics Laboratory. The Epi proColon Septin 9 Methylation Analysis test is indicated to screen adults of either sex, 50 years or older, defined as average risk for colorectal cancer (CRC), who have been offered and have a history of not completing CRC screening.
Effective September 23, 2016, Spectrum Health Regional Laboratory Molecular Diagnostics Department is pleased to announce that the HIV-1 Quantitative RNA PCR (Test Code #7125) has been added to our in-house test menu.
Spectrum Health Regional Laboratory (SHRL) was featured on Medical Moment on Fox 17 News, Monday, September 19, 2016. Watch the clip below to go behind the scenes of our Advanced Technology Laboratories with Kim Collison, Director of Laboratory Services. Learn how ATL provides rapid turn-around of unique testing performed right here in West Michigan, which supports many key services such as oncology.
For more information on the testing that SHRL and ATL offer, please visit our Laboratory Catalog.
Spectrum Health Regional Laboratory (SHRL) was featured on EightWest on WOOD TV8 on Tuesday, August 30, 2016. Dr. Stephanie F. Williams, Division Chief of Spectrum Health Adult Bone and Marrow Transplant, and Kim Collison, Director of Laboratory Services, talk about the importance and benefits of having SHRL’s Advanced Technology Laboratory right here in West Michigan.
The Advanced Technology Laboratory is “extremely important, particularly for patients with certain cancers…”
“It helps us to diagnose the patients faster and more accurately; to follow the progress of their disease during the treatments that we give, and even at times to guide us in what is the best treatment for a patient…”
“Within 2 hours we had the answer. We did not have to send that specimen out to another laboratory in another state.”
-Stephanie F. Williams, MD, Division Chief, Spectrum Health Adult Bone and Marrow Transplant
Effective June 6, 2016, Spectrum Health Regional Laboratory Molecular Diagnostics Department is pleased to announce the addition of the MPN Expanded Panel (Test #7090, Epic #LAB3611).
The treatment of non-small cell lung adenocarcinoma has become more successful due to targeted treatments based on the molecular profile of a patient’s particular tumor. The Lung Cancer Mutation Analysis panel is now available for clinical testing at the Spectrum Health Advanced Technology Laboratories (ATL).
The Spectrum Health Laboratory is now reporting all Hepatitis C Antibody results as Negative or Positive only. (Hepatitis C Antibody, Screening; Hepatitis C Antibody, Diagnostic) The separate Low Positive result category has been eliminated.
The Laboratory has changed to a new Hepatitis C Antibody reagent which no longer includes the Low Positive result category in its product labeling (the FDA approved instructions which laboratories are required to follow). The Low Positive category was defined on the basis of old guidelines which indicated that results above a defined S/CO (signal/cutoff) value were considered to have a 95% or greater probability of being true positives and did not require RIBA confirmation. The RIBA confirmatory test has not been available for several years now. Current guidelines are that all positive Hepatitis C Antibody tests should be confirmed with a HCV RNA test. The Spectrum Health laboratory reflexes all positive antibody results to this test. A positive HCV RNA following a positive antibody result should be considered indicative of active HCV infection, and may be used as a baseline for antiviral therapy.